Control of the coagulation system by serpins: Getting by with a little help from glycosaminoglycans

FEBS Journal

Volumn 272, Issue 19, 2005, Pages 4842-4851

  Pike, Robert N ^a   Buckle, Ashley M ^a   Le Bonniec, Bernard F ^b   Church, Frank C ^c  

^a MONASH UNIVERSITY   (Australia)

^b INSERM   (France)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antithrombin; Coagulation; Glycosaminoglycans; Heparin cofactor II; Proteases; Protein C inhibitor; Serpins; Thrombin

Indexed keywords

ANTITHROMBIN; GLYCOSAMINOGLYCAN; HEPARIN COFACTOR II; PLASMINOGEN ACTIVATOR INHIBITOR 3; SERINE PROTEINASE INHIBITOR; THROMBIN; THROMBOMODULIN;

ANTICOAGULATION; CHEMICAL ANALYSIS; CONFERENCE PAPER; ENZYME ACTIVITY; HUMAN; PRIORITY JOURNAL;

ANIMALS; BLOOD COAGULATION; GLYCOSAMINOGLYCANS; HUMANS; SERINE PROTEINASE INHIBITORS; SERPINS;

EID: 26244432935     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2005.04880.x     Document Type: Conference Paper

References (100)

1. Spronk HM, Govers-Riemslag JW & ten Cate H (2003) The blood coagulation system as a molecular machine. BioEssays 25, 1220-1228.
2. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PGW et al. (2001) The serpins are an expanding superfamily of structurally similar but functionally diverse proteins: Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 276, 33293-33296.
3. Huntington JA (2003) Mechanisms of glycosaminoglycan activation of the serpins in hemostasis. J Thromb Haemost 1, 1535-1549.
4. Gettins PG (2002) Serpin structure, mechanism, and function. Chem Rev 102, 4751-4804.
5. Ye S, Cech AL, Belmares R, Bergstrom RC, Tong Y, Corey DR, Kanost MR & Goldsmith EJ (2001) The structure of a Michaelis serpin-protease complex. Nat Struct Biol 8, 979-983.
6. Kaslik G, Kardos J, Szabo E, Szilagyi L, Zavodszky P, Westler WM, Markley JL & Graf L (1997) Effects of serpin binding on the target proteinase: global stabilization, localized increased structural flexibility, and conserved hydrogen bonding at the active site. Biochemistry 36, 5455-5464.
7. Huntington JA, Read RJ & Carrell RW (2000) Structure of a serpin-protease complex shows inhibition by deformation, Nature 407.
8. Stein PE & Carrell RW (1995) What do dysfunctional serpins tell us about molecular mobility and disease? Struct Biol 2, 96-113.
9. Conard J, Brosstad F, Lie Larsen M, Samama M & Abildgaard U (1983) Molar antithrombin concentration in normal human plasma. Haemostasis 13, 363-368.
10. Skinner R, Abrahams JP, Whisstock JC, Lesk AM, Carrell RW & Wardell MR (1997) The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site. J Mol Biol 266, 601-609.
11. Huntington JA, Olson ST, Fan B & Gettins PG (1996) Mechanism of heparin activation of antithrombin. Evidence for reactive center loop preinsertion with expulsion upon heparin binding. Biochemistry 35, 8495-8503.
12. Jin L, Abrahams JP, Skinner R, Petitou M & Pike RN (1997) The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA 94, 14683-14688.
13. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B & Gatti G (1983) Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 116, 492-499.
14. Desai UR, Petitou M, Bjork I & Olson ST (1998) Mechanism of heparin activation of antithrombin. Role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin. J Biol Chem 273, 7478-7487.
15. Olson ST, Bjork I, Sheffer R, Craig PA, Shore JD & Choay J (1992) Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 267, 12528-12538.
16. Quinsey NS, Whisstock JC, Le Bonniec B, Louvain V, Bottomley SP & Pike RN (2002) Molecular determinants of the mechanism underlying acceleration of the interaction between antithrombin and factor Xa by heparin pentasaccharide. J Biol Chem 277, 15971-15978.
17. Rezaie AR, Yang L & Manithody C (2004) Mutagenesis studies toward understanding the mechanism of differential reactivity of factor Xa with the native and heparin-activated antithrombin. Biochemistry 43, 2898-2905.
18. Chuang YJ, Swanson R, Raja SM & Olson ST (2001) Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence. Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin. J Biol Chem 276, 14961-14971.
19. Izaguirre G, Zhang W, Swanson R, Bedsted T & Olson ST (2003) Localization of an antithrombin exosite that promotes rapid inhibition of factors Xa and IXa dependent on heparin activation of the serpin. J Biol Chem 278, 51433-51440.
20. The Rembrandt Investigators. (2000) Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: a phase II evaluation. Circulation 102, 2726-2731.
21. Olson ST & Shore JD (1982) Demonstration of a two-step reaction mechanism for inhibition of alpha-thrombin by antithrombin III and identification of the step affected by heparin. J Biol Chem 257, 14891-14895.
22. Rezaie AR (1998) Calcium enhances heparin catalysis of the antithrombin-Factor Xa reaction by a template mechanism: Evidence that calcium alleviates Gla domain antagonism of heparin binding to Factor Xa. J Biol Chem 273, 16824-16827.
23. Lane DA, Olds R & Thein S-L (1992) Antithrombin and its deficiency states. Blood Coag Fibrinol 3, 315-341.
24. Li W, Johnson DJ, Esmon CT & Huntington JA (2004) Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin, Nat Struct Mol Biol 11, 857-862.
25. Dementiev A, Petitou M, Herbert JM & Gettins PG (2004) The ternary complex of antithrombin-anhydrothrombin-heparin reveals the basis of inhibitor specificity. Nat Struct Mol Biol 11, 863-867.
26. Weitz JI, Hudoba M, Massel D, Maraganore J & Hirsh J (1990) Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 86, 385-391.
27. Rezaie AR (2001) Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood 97, 2308-2313.
28. Mertens G, Cassiman J-J, Van den Berghe H, Vermylen J & David G (1992) Cell surface heparan sulfate proteoglycans from human vascular endothelial cells: core protein characterization and antithrombin III binding properties. J Biol Chem 267, 20435-20443.
29. Scully MF, Ellis V, Shah N & Kakkar V (1989) Effect of a heparan sulphate with high affinity for antithrombin III upon inactivation of thrombin and coagulation factor Xa. Biochem J 262, 651-658.
30. Ishiguro K, Kojima T, Kadomatsu K, Nakayama Y, Takagi A, Suzuki M et al. (2000) Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest 106, 873-878.
31. Yanada M, Kojima T, Ishiguro K, Nakayama Y, Yamamoto K, Matsushita T et al. (2002) Impact of antithrombin deficiency in thrombogenesis: lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombin-deficient mice. Blood 99, 2455-2458.
32. Beauchamp NJ, Pike RN, Daly M, Butler L, Markis M, Daffron TR et al. (1998) Antithrombins Wibble and Wobble (T85M/K): Archetypal conformational diseases with in vivo latent-transition, thrombosis and heparin activation. Blood 92, 2696-2706.
33. Tollefsen DM & Pestka CA (1985) Heparin cofactor II activity in patients with disseminated intravascular coagulation and hepatic failure. Blood 66, 769-774.
34. Blinder MA, Marasa JC, Reynolds CH, Deaven LL & Tollefsen DM (1988) Heparin cofactor II: cDNA sequence, chromosome localization, restriction fragment length polymorphism, and expression in Escherichia coli. Biochem 27, 752-759.
35. Griffith MJ, Noyes CM, Tyndall JA & Church FC (1985) Structural evidence for leucine at the reactive site of heparin cofactor II. Biochemistry 24, 6777-6782.
36. Church FC, Noyes CM & Griffith MJ (1985) Inhibition of chymotrypsin by heparin cofactor II. Proc Natl Acad Sci USA 82, 6431-6434.
37. Parker KA & Tollefsen DM (1985) The protease specificity of heparin cofactor II. Inhibition of thrombin generated during coagulation. J Biol Chem 260, 3501-3505.
38. Pratt CW, Whinna HC, Meade JM, Treanor RE & Church FC (1989) Physicochemical aspects of heparin cofactor II. Ann NY Acad Sci 556, 104-114.
39. Tollefsen DM (1997) Heparin cofactor II. Adv Exp Med Biol 425, 35-44.
40. Baglin TP, Carrell RW, Church FC, Esmon CT & Huntington JA (2002) Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism. Proc Natl Acad Sci USA 99, 11079-11084.
41. Blinder MA & Tollefsen DM (1990) Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II. J Biol Chem 265, 286-291.
42. Fortenberry YM, Whinna HC, Gentry HR, Myles T, Leung LL & Church FC (2004) Molecular mapping of the thrombin-heparin cofactor II complex. J Biol Chem 279, 43237-43244.
43. Jeter ML, Ly LV, Fortenberry YM, Whinna HC, White RR, Rusconi CP, Sullenger BA & Church FC (2004) RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins. FEBS Lett 568, 10-14.
44. Liaw PCY, Austin RC, Fredenburgh JC, Stafford AR & Weitz JI (1999) Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II. J Biol Chem 274, 27597-27604.
45. Myles T, Church FC, Whinna HC, Monard D & Stone SR (1998) Role of thrombin anion-binding exosite-I in the formation of thrombin-serpin complexes. J Biol Chem 273, 31203-31208.
46. Ragg H, Ulshofer T & Gerewitz J (1990) On the activation of human leuserpin-2, a thrombin inhibitor, by glycosaminoglycans. J Biol Chem 265, 5211-5218.
47. Ragg H, Ulshofer T & Gerewitz J (1990) Glycosaminoglycan-mediated leuserpin-2/thrombin interaction: Structure x function relationships. J Biol Chem 265, 22386-22391.
48. Rogers SJ, Pratt CW, Whinna HC & Church FC (1992) Role of thrombin exosites in inhibition by heparin cofactor II. J Biol Chem 267, 3613-3617.
49. Sheehan JP, Tollefsen DM & Sadler JE (1994) Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans. J Biol Chem 269, 32747-32751.
50. Sheehan JP, Wu Q, Tollefsen DM & Sadler JE (1993) Mutagenesis of thrombin selectively modulates inhibition by serpins heparin cofactor II and antithrombin III. Interaction with the anion-binding exosite determines heparin cofactor II specificity. J Biol Chem 268, 3639-3645.
51. VanDeerlin VMD & Tollefsen DM (1991) The N-terminal acidic domain of heparin cofactor II mediates the inhibition of α-thrombin in the presence of glycosaminoglycans. J Biol Chem 266, 20223-20231.
52. Whinna HC, Blinder MA, Szewczyk M, Tollefsen DM & Church FC (1991) Role of lysine 173 in heparin binding to heparin cofactor II. J Biol Chem 266, 8129-8135.
53. Verhamme IM, Bock PE & Jackson CM (2004) The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II. J Biol Chem 279, 9785-9795.
54. Inhorn RC & Tollefsen DM (1986) Isolation and characterization of a partial cDNA clone for heparin cofactor II. Biochem Biophys Res Commun 137, 431-436.
55. Ragg H (1986) A new member of the plasma protease inhibitor gene family. Nuc Acids Res 14, 1073-1087.
56. Tollefsen DM, Pestka CA & Monafo WJ (1983) Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 258, 6713-6716.
57. Tollefsen DM, Peacock ME & Monafo WJ (1986) Molecular size of dermatan sulfate oligosaccharides required to bind and activate heparin cofactor II. J Biol Chem 261, 8854-8858.
58. McGuire EA & Tollefsen DM (1987) Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells. J Biol Chem 262, 169-175.
59. Tollefsen DM, Maimone MM, McGuire EA & Peacock ME (1989) Heparin cofactor II activation by dermatan sulfate. Ann N Y Acad Sci 556, 116-122.
60. Maimone MM & Tollefsen DM (1990) Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity. J Biol Chem 265, 18263-18271.
61. Pratt CW, Whinna HC & Church FC (1992) A comparison of three heparin-binding serine proteinase inhibitors. J Biol Chem 267, 8795-8801.
62. Whinna HC, Choi HU, Rosenberg LC & Church FC (1993) Interaction of heparin cofactor II with biglycan and decorin. J Biol Chem 268, 3920-3924.
63. Shirk RA, Church FC & Wagner WD (1996) Arterial smooth muscle cell heparan sulfate proteoglycans accelerate thrombin inhibition by heparin cofactor II. Arterioscler Thromb Vasc Biol 16, 1138-1146.
64. Shirk RA, Parthasarathy N, San Antonio JD, Church FC & Wagner WD (2000) Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque. J Biol Chem 275, 18085-18092.
65. He L, Vicente CP, Westrick RJ, Eitzman DT & Tollefsen DM (2002) Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest 109, 213-219.
66. Vicente CP, He L, Pavao MS & Tollefsen DM (2004) Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice. Blood 104, 3965-3970.
67. Suzuki K, Deyashiki Y, Nishioka J & Toma K (1989) Protein C inhibitor: structure and function. Thromb Haemostas 61, 337-342.
68. Laurell M & Stenflo J (1989) Protein C inhibitor from human plasma: characterization of native and cleaved inhibitor and demonstration of inhibitor complexes with plasma kallikrein. Thromb Haemostasis 62, 885-891.
69. Espana F, Gruber A, Heeb M, Hanson S, Harker L & Griffin J (1991) In vivo and in vitro complexes of activated protein C with two inhibitors in baboons. Blood 77, 1754-1760.
70. Geiger M, Priglinger U, Griffin JH & Binder BR (1991) Urinary protein C inhibitor. Glycosaminoclycans synthesized by the epithelial kidney cell line TCL-598 enhance its interaction with urokinase. J Biol Chem 266, 11851-11857.
71. Ecke S, Geiger M, Resch I, Jerabek I, Stingl L, Maier M & Binder BR (1992) Inhibition of tissue kallikrein by protein C inhibitor. Evidence for identity of protein C inhibitor with the kallikrein binding protein. J Biol Chem 267, 7048-7052.
72. Laurell M, Christensson A, Abrahamsson PA, Stenflo J & Lilja H (1992) Protein C inhibitor in human body fluids. Seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive system. J Clin Invest 89, 1094-1101.
73. Radtke KP, Fernandez JA, Greengard JS, Tang WW, Wilson CB, Loskutoff DJ, Scharrer I & Griffin JH (1994) Protein C inhibitor is expressed in tubular cells of human kidney. J Clin Invest 94, 2117-2124.
74. Hermans JM, Jones R & Stone SR (1994) Rapid inhibition of the sperm protease acrosin by protein C inhibitor. Biochemistry 33, 5440-5444.
75. Espana F, Sanchez-Cuenca J, Fernandez PJ, Gilabert J, Romeu A, Estelles A, Royo M & Muller CH (1999) Inhibition of human sperm-zona-free hamster oocyte binding and penetration by protein C inhibitor. Andrologia 31, 217-223.
76. Uhrin P, Dewerchin M, Hilpert M, Chrenek P, Schofer C, Zechmeister-Machhart M et al. (2000) Disruption of the protein C inhibitor gene results in impaired spermatogensis and male infertility. J Clin Invest 106, 1531-1539.
77. Suzuki K, Nishioka J & Hashimoto S (1983) Protein C inhibitor: purification from human plasma and characterization. J Biol Chem 258, 163-168.
78. Suzuki K, Deyashiki Y, Nishioka J, Kurachi K, Akira M, Yamamoto S & Hashimoto S (1987) Characterization of a cDNA for human protein C inhibitor. A new member of the plasma serine protease inhibitor superfamily. J Biol Chem 262, 611-616.
79. Suzuki K (1984) Activated protein C inhibitor. Semin Thrombos Hemostas 10, 154-161.
80. Heeb MJ, Espana F, Geiger M, Collen D, Stump DC & Griffin JH (1987) Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3. J Biol Chem 262, 15813-15816.
81. Geiger M, Heeb MJ, Binder BR & Griffin JH (1988) Competition of activated protein C and urokinase for a heparin-dependent inhibitor. FASEB J 2, 2263-2267.
82. Meijers JCM, Kanters DHAJ, Vlooswijk RAA, van Erp HE, Hessing M & Bouma BN (1988) Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor. Biochemistry 27, 4231-4237.
83. Heeb MJ, Espana F & GJ (1989) Inhibition and complexation of activated protein C by two major inhibitors in plasma. Blood 73, 446-454.
84. Rezaie AR, Cooper ST, Church FC & Esmon CT (1995) Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J Biol Chem 270, 25336-25339.
85. Elisen MG, van Kooij RJ, Nolte MA, Marquart JA, Lock TM, Bouma BN & Meijers JC (1998) Protein C inhibitor may modulate human sperm-oocyte interactions. Biol Reprod 58, 670-677.
86. Elisen MG, dem Borne PA, Bouma BN & Meijers JC (1998) Protein C inhibitor acts as a procoagulant by inhibiting the thrombomodulin-induced activation of protein C in human plasma. Blood 91, 1542-1547.
87. Elisen MGLM, Bouma BN, Church FC & Meijers JCM (1998) Inhibition of serine proteases by reactive site mutants of protein C inhibitor (plasminogen activator inhibitor-3). Fib Prot 12, 283-291.
88. Shen L, Villoutreix BO & Dahlback B (1999) Involvement of Lys 62 (217) and Lys 63 (218) of human anticoagulant protein C in heparin stimulation of inhibition by the protein C inhibitor. Thromb Haemost 82, 72-79.
89. Friedrich U, Blom AM, Dahlbäck B & Villoutreix BO (2001) Structural and energetic characteristics of the heparin-binding site in antithrombotic protein C. J Biol Chem 276, 24122-24128.
90. Mosnier LO, Elisen MG, Bouma BN & Meijers JC (2001) Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regulation of TAFI activation. Thromb Haemost 86, 1057-1064.
91. Rezaie AR (2003) Exosite-dependent regulation of the protein C anticoagulant pathway. Trends Cardiovasc Med 13, 8-15.
92. Kuhn LA, Griffin JH, Fisher CL, Greengard JS, Bouma BN, Espana F & Tainer JA (1990) Elucidating the structural chemistry of glycosaminoglycan recognition by protein C inhibitor. Proc Natl Acad Sci USA 87, 8506-8510.
93. Shirk RA, Elisen MGLM, Meijers JCM & Church FC (1994) Role of the H helix in heparin binding to protein C inhibitor. J Biol Chem 269, 28690-28695.
94. Cooper ST, Whinna HC, Jackson TP, Boyd JM & Church FC (1995) Intermolecular interactions between protein C inhibitor and coagulation proteases. Biochemistry 34, 12991-12997.
95. Elisen MGLM, Maseland MHH, Church FC, Bouma BN & Meijers JCM (1996) Role of the A+ helix in heparin binding to protein C inhibitor. Thromb Haemost 75, 760-766.
96. Neese LL, Wolfe CA & Church FC (1998) Contribution of basic residues of the D and H helices in heparin binding to protein C inhibitor. Arch Biochem Biophys 355, 101-108.
97. Huntington JA, Kjellberg M & Stenflo J (2003) Crystal structure of protein C inhibitor provides insights into hormone binding and heparin activation. Structure (Camb) 11, 205-215.
98. Pratt CW & Church FC (1992) Heparin binding to protein C inhibitor. J Biol Chem 267, 8789-8794.
99. Yang L, Manithody C, Walston TD, Cooper ST & Rezaie AR (2003) Thrombomodulin enhances the reactivity of thrombin with protein C inhibitor by providing both a binding site for the serpin and allosterically modulating the activity of thrombin. J Biol Chem 278, 37465-37470.
100. Priglinger U, Geiger M, Bielek E, Vanyek E & Binder BR (1994) Binding of urinary protein C inhibitor to cultured human epithelial kidney tumor cells (TCL-598). The role of glycosaminoglycans present on the luminal cell surface. J Biol Chem 269, 14705-14710.